Aspire Biopharma Holdings Inc (ASBP) FinancialsASBPAspire Biopharma Holdings Inc

Evaluating the bottom line, Aspire Biopharma Holdings Inc maintains a gross margin of -47.68%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -3880.58%, while the net margin is -2009.61%. These profitability ratios, combined with a Return on Equity (ROE) of -1032.14%, provide a clear picture of how effectively ASBP converts its operational activities into shareholder value.

In the context of the broader market, ASBP competes directly with industry leaders such as MTEX and BNKK. With a market capitalization of $11.94M, it holds a significant position in the sector. When comparing efficiency, ASBP's gross margin of -47.68% stands against MTEX's 76.87% and BNKK's 33.61%. Such benchmarking helps identify whether Aspire Biopharma Holdings Inc is trading at a premium or discount relative to its financial performance.

PowerUp Acquisition Corp has shown inconsistent financial performance, with total revenue starting to increase in 2026 but still reporting a net loss of -1,268,142 USD in Q2 2026. The gross margin has fluctuated significantly, reaching -47.68% in the latest quarter, indicating challenges in profitability.